A breathable treatment for a disease that slowly steals breath is nearing approval – and could reframe how doctors think about aging lungs.
Idiopathic pulmonary fibrosis creeps in as a cough, then a bit of breathlessness on the stairs, then something far more serious: scar tissue quietly replacing the delicate, oxygen-trading surfaces of the lungs. There is no known cause, which is what “idiopathic” means, though age is the biggest risk factor by far; the disease rarely shows up before 50.
For the roughly 100,000 Americans estimated to be living with it, and the millions more worldwide facing similar fibrotic lung conditions, treatment options have long been limited to slowing the inevitable rather than reversing it.
That’s what makes this news notable. United Therapeutics announced that the US Food and Drug Administration (FDA) has accepted its supplemental application to expand the use of nebulized Tyvaso, an inhaled medication already approved for pulmonary hypertension, to include IPF [1]. If cleared, it would become the first and only inhaled anti-fibrotic treatment for the disease. The agency’s review is expected to wrap up by late April 2027.
Tyvaso works by mimicking a naturally occurring compound called prostacyclin, delivered directly to the lungs through a nebulizer rather than pumped through the whole body via a pill or injection. The company’s pitch is that this local delivery lets the drug act on several of the pathways that drive fibrosis at once: the fibrous scarring itself, the blood vessel changes and the inflammation, instead of targeting just one.
The case for expanding its use rests on two large phase 3 trials, TETON-1 and TETON-2, which together enrolled patients with IPF across the globe. When researchers pooled the results, patients on nebulized Tyvaso saw significantly better outcomes on the primary measure doctors use to track the disease: the change in forced vital capacity, essentially how much air the lungs can hold and move.
The combined analysis showed an improvement of 111.8 milliliters over placebo, a statistically significant difference that held up at the 95 percent confidence level. Patients on the drug also had a reduced risk of a clinical worsening event and of an acute flare-up of the disease, along with better scores on a standard quality-of-life questionnaire for lung disease.
Those findings were significant enough to be presented at the American Thoracic Society’s 2026 meeting and published simultaneously in The New England Journal of Medicine, a marker of how seriously the pulmonary research community is taking the data.
“Nebulized Tyvaso combines direct lung delivery with multimodal activity across fibrotic, vascular, and inflammatory pathways that are central to IPF, with the potential to help address a significant unmet need for this life-threatening disease,” said Dr Martine Rothblatt, chairperson and CEO of United Therapeutics.
It’s worth sitting with why a lung drug belongs in a conversation about longevity. Pulmonary fibrosis is, in a sense, a case study in accelerated aging: tissue that loses its capacity to repair itself and instead scars over, function declining faster than the calendar would predict. Treatments that can meaningfully slow or interrupt that process don’t just add months to a patient’s life; they preserve the everyday physical capacity, the ability to climb stairs, play with grandchildren or simply breathe without effort, that defines what researchers increasingly call healthspan rather than lifespan.
An approved anti-fibrotic therapy for the lungs would also stand as proof of concept that fibrosis, a process implicated in aging hearts, kidneys, and liver tissue as much as lungs, can be targeted directly rather than just managed.
There’s still a long road ahead. Nebulized Tyvaso remains investigational for IPF, and a separate study, TETON-PPF, is currently evaluating the drug in progressive pulmonary fibrosis more broadly, with enrollment already complete. An open-label extension study is also tracking long-term safety in patients who completed the original trials. Both the FDA and the European Medicines Agency have granted the drug orphan status for IPF, a designation reserved for treatments aimed at rare, serious conditions.
For now, the milestone is procedural: the FDA has agreed to review the application. But for a disease with so few treatment options, and for a field increasingly focused on how the body ages tissue by tissue, the acceptance of this filing is a meaningful step toward a therapy that could let more people simply keep breathing easy.
